Fig. 1: Structure of T-DM1.
From: Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
T-DM1 is comprised of the monoclonal antibody trastuzumab conjugated via a non-cleavable MCC thioether linker to 3–3.6 moieties of the potent tubulin polymerisation inhibitor mertansine (DM1).
